Clover Health Investments Analyst Ratings
Clover Health Investments Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/11/2023 | 13.64% | Citigroup | $1 → $1.5 | Maintains | Neutral |
| 03/06/2023 | 127.27% | Canaccord Genuity | $4 → $3 | Maintains | Buy |
| 03/06/2023 | -5.3% | Credit Suisse | $2.5 → $1.25 | Maintains | Underperform |
| 11/16/2022 | 36.36% | Citigroup | $3.5 → $1.8 | Maintains | Neutral |
| 11/08/2022 | 13.64% | SVB Leerink | $3 → $1.5 | Maintains | Market Perform |
| 08/09/2022 | 165.15% | Citigroup | $3 → $3.5 | Maintains | Neutral |
| 08/09/2022 | 127.27% | Credit Suisse | $3.5 → $3 | Maintains | Underperform |
| 05/10/2022 | 127.27% | SVB Leerink | $2.5 → $3 | Maintains | Market Perform |
| 02/25/2022 | 89.39% | SVB Leerink | $3 → $2.5 | Maintains | Market Perform |
| 02/02/2022 | 354.55% | Canaccord Genuity | → $6 | Initiates Coverage On | → Buy |
| 02/02/2022 | 127.27% | Cowen & Co. | $7 → $3 | Upgrades | Underperform → Market Perform |
| 01/19/2022 | 127.27% | SVB Leerink | → $3 | Initiates Coverage On | → Market Perform |
| 01/07/2022 | 165.15% | Credit Suisse | $9 → $3.5 | Downgrades | Neutral → Underperform |
| 11/15/2021 | 581.82% | Credit Suisse | $8 → $9 | Maintains | Neutral |
| 09/10/2021 | 430.3% | Cowen & Co. | → $7 | Initiates Coverage On | → Underperform |
| 07/12/2021 | 581.82% | JP Morgan | → $9 | Downgrades | Neutral → Underweight |
| 06/10/2021 | 657.58% | B of A Securities | → $10 | Downgrades | Neutral → Underperform |
| 05/19/2021 | 581.82% | Credit Suisse | $10 → $9 | Maintains | Neutral |
| 05/17/2021 | 581.82% | B of A Securities | $15 → $9 | Downgrades | Buy → Neutral |
| 03/09/2021 | 657.58% | Credit Suisse | → $10 | Initiates Coverage On | → Neutral |
| 02/02/2021 | 1339.39% | Citigroup | → $19 | Initiates Coverage On | → Buy |
| 02/01/2021 | 1036.36% | JP Morgan | → $15 | Initiates Coverage On | → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/11/2023 | 13.64% | 花旗集團 | $1 → 1.5 美元 | 維護 | 中立 |
| 03/06/2023 | 127.27% | Canaccord Genu | 4 美元 → 3 美元 | 維護 | 購買 |
| 03/06/2023 | -5.3% | 瑞士信貸 | 2.5 美元 → 1.25 美元 | 維護 | 表現不佳 |
| 11/16/2022 | 36.36% | 花旗集團 | 3.5 美元 → 1.8 美元 | 維護 | 中立 |
| 2022 年 8 月 11 日 | 13.64% | SVB Leerink | $3 → 1.5 美元 | 維護 | 市場表現 |
| 08/09/2022 | 165.15% | 花旗集團 | 3 美元 → 3.5 美元 | 維護 | 中立 |
| 08/09/2022 | 127.27% | 瑞士信貸 | 3.5 美元 → 3 美元 | 維護 | 表現不佳 |
| 05/10/2022 | 127.27% | SVB Leerink | 2.5 美元 → 3 美元 | 維護 | 市場表現 |
| 2022 年 2 月 25 日 | 89.39% | SVB Leerink | $3 → 2.5 美元 | 維護 | 市場表現 |
| 02/02/2022 | 354.55% | Canaccord Genu | → 6 美元 | 啓動覆蓋開啓 | → 購買 |
| 02/02/2022 | 127.27% | Cowen & Co. | 7 美元 → 3 美元 | 升級 | 表現不佳 → 市場表現 |
| 2022 年 1 月 19 日 | 127.27% | SVB Leerink | → 3 美元 | 啓動覆蓋開啓 | → 市場表現 |
| 2022 年 7 月 1 日 | 165.15% | 瑞士信貸 | 9 美元 → 3.5 美元 | 降級 | 中性 → 跑贏大盤 |
| 11/15/2021 | 581.82% | 瑞士信貸 | 8 美元 → 9 美元 | 維護 | 中立 |
| 2021 年 10 月 9 日 | 430.3% | Cowen & Co. | → 7 美元 | 啓動覆蓋開啓 | → 表現不佳 |
| 2021 年 12 月 7 日 | 581.82% | 摩根大通 | → 9 美元 | 降級 | 中性 → 體重不足 |
| 06/10/2021 | 657.58% | B of A 類證券 | → 10 美元 | 降級 | 中性 → 跑贏大盤 |
| 2021 年 5 月 19 日 | 581.82% | 瑞士信貸 | 10 美元 → 9 美元 | 維護 | 中立 |
| 05/17/2021 | 581.82% | B of A 類證券 | 15 美元 → 9 美元 | 降級 | 買入 → 中性 |
| 2021 年 9 月 3 日 | 657.58% | 瑞士信貸 | → 10 美元 | 啓動覆蓋開啓 | → 中立 |
| 2021 年 2 月 2 日 | 1339.39% | 花旗集團 | → 19 美元 | 啓動覆蓋開啓 | → 購買 |
| 2021 年 1 月 2 日 | 1036.36% | 摩根大通 | → 15 美元 | 啓動覆蓋開啓 | → 中立 |
What is the target price for Clover Health Investments (CLOV)?
Clover Health Investments（CLOV）的目標價格是多少？
The latest price target for Clover Health Investments (NASDAQ: CLOV) was reported by Citigroup on August 11, 2023. The analyst firm set a price target for $1.50 expecting CLOV to rise to within 12 months (a possible 13.64% upside). 5 analyst firms have reported ratings in the last year.
花旗集團於2023年8月11日公佈了Clover Health Investments（納斯達克股票代碼：CLOV）的最新目標股價。這家分析公司將目標股價定爲1.50美元，預計CLOV將在12個月內升至12個月內（可能上漲13.64％）。去年有5家分析公司公佈了評級。
What is the most recent analyst rating for Clover Health Investments (CLOV)?
分析師對Clover Health Investments（CLOV）的最新評級是多少？
The latest analyst rating for Clover Health Investments (NASDAQ: CLOV) was provided by Citigroup, and Clover Health Investments maintained their neutral rating.
Clover Health Investments（納斯達克股票代碼：CLOV）的最新分析師評級由花旗集團提供，三葉草健康投資維持中性評級。
When is the next analyst rating going to be posted or updated for Clover Health Investments (CLOV)?
Clover Health Investments（CLOV）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Clover Health Investments, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Clover Health Investments was filed on August 11, 2023 so you should expect the next rating to be made available sometime around August 11, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Clover Health Investments的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應該獲得4個評級。Clover Health Investments的最新評級是在2023年8月11日提交的，因此您應該預計下一個評級將在2024年8月11日左右公佈。
Is the Analyst Rating Clover Health Investments (CLOV) correct?
分析師對三葉草健康投資（CLOV）的評級正確嗎？
While ratings are subjective and will change, the latest Clover Health Investments (CLOV) rating was a maintained with a price target of $1.00 to $1.50. The current price Clover Health Investments (CLOV) is trading at is $1.32, which is within the analyst's predicted range.
儘管評級是主觀的，將會發生變化，但最新的Clover Health Investments（CLOV）評級維持不變，目標股價爲1.00美元至1.50美元。Clover Health Investments（CLOV）目前的交易價格爲1.32美元，在分析師的預測區間內。